Thus, it seems that Kim and Turrini’s cohorts are not comparable to ours, at least in terms of tumour grade, which might explain the different prognosis value of KRAS mutation presence in margins, which may be of clinical value for lower grade PDACs. The gene discussed is KRAS; the disease is neoplasm.